Our Latest News - BUHLMANN

Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring

IBDoc® Citation: Wei, S. , Tung, C. et al. Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring. Intestinal Research 2018;16(4):546-553. DOI: https://doi.org/10.5217/ir.2018.00052 PMID: 30301339 Highlights from this Publication “96% of the patients were satisfied with the home test..." “71% of patients preferred the home test method monitor

Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis

IBDoc® Citation: Walsh, A, Kormilitzin, A et al. Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis—a Prospective Analysis, Journal of Crohn's and Colitis, jjy184, PMID: 30445625 DOI: doi.org/10.1093/ecco-jcc/jjy184 Highlights from this Publication “This is the first prospective study to use validated endoscopic and histologic indices to determine the thresholds of

IBDoc Canadian User Performance Evaluation

IBDoc® Citation: Alice C Moore, Vivian W Huang, Raymond Bourdages, Richard N Fedorak, Christian Reinhard, Yvette Leung, Brian Bressler, Greg Rosenfeld; IBDoc Canadian User Performance Evaluation, Inflammatory Bowel Diseases, , izy357, DOI: https://doi.org/10.1093/ibd/izy357 PMID: 30535387 Highlights from this Publication "The majority of patients found it easy-to-use and felt that most patients would be able to learn how to

Clinical Trial Combines New Symptom App with IBDoc

Read a recent article from University of Otago on the success of a new smartphone app, IBDSmart, in synergy with BÜHLMANN IBDoc calprotectin home test. Highlight from this Article "The study showed there was no difference in terms of quality of life for patients whether they used the apps or had face-to-face meetings,” Associate Professor

BUHLMANN fCAL® turbo (calprotectin)

BÜHLMANN fCAL® turbo BÜHLMANN fCAL® turbo (K190784): FDA 510(k) cleared. For in vitro Diagnostic Use. BÜHLMANN fCAL® turbo + CALEX® Cap (K191718 & K232057): FDA 510(k) cleared. For in vitro Diagnostic Use. CPT Code: Calprotectin – 83993 fecal Calprotectin (fCAL)- An FDA Cleared Gastrointestinal Test to Distinguish IBD from IBS Calprotectin is a highly-sensitive clinical biomarker that has

LabSense News Fall 2018 Edition

IBDoc® Talk – Tips and Tricks Teleconference

Health Canada Licence: 98903, Device class: 3 BÜHLMANN IBDoc® is not available for sale in the US. IBDoc® is the first self-testing application for fecal calprotectin in IBD patients that involves three easy steps. IBDoc® allows IBD patients convenient self-testing of fecal calprotectin. Teleconference Overview Goal of Discussion The goal was for Clinical Administrators and Clinical Users from

BUHLMANN Quantum Blue® fCAL Tutorial

View this demonstration of CALEX® Cap extraction and quantitative fecal calprotectin measurement using the Quantum Blue® fCAL rapid test technology. Quantum Blue® fCAL high range: Health Canada License: 88674 Quantum Blue® fCAL: Health Canada License: 83477 US: (The Quantum Blue® tests are for Research Use Only. Not for use in diagnostic procedures in the US.) Contact BUHLMANN Today! Contact

Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn’s disease.

BÜHLMANN fCAL® ELISA Citation Pavlidis, P. et al., 2016, Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn’s disease, Scandinavian Journal of Gastroenterology. PMID: 27400728 DOI: 10.1080/00365521.2016.1205128 Highlight from this Publication “The ΔFCAL could act as an ‘early warning’ to consider alternatives such as dose optimisation or another biologic with a different mode of action,

Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study.

BÜHLMANN fCAL® ELISA Citation Lasson, A. et al., 2014, Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of relapse: A prospective, randomized, controlled study, United European Gastroenterology Journal. PMID: 25653861 DOI: 10.1177/2050640614560785 Highlight from this Publication “In patients with UC, FC-guided dosing of the patient’s 5-ASA agent showed significantly lower relapse rates than

BUHLMANN News

Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring

Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis

IBDoc Canadian User Performance Evaluation

Clinical Trial Combines New Symptom App with IBDoc

BUHLMANN fCAL® turbo (calprotectin)

LabSense News Fall 2018 Edition

IBDoc® Talk – Tips and Tricks Teleconference

BUHLMANN Quantum Blue® fCAL Tutorial

Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn’s disease.

Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study.

ABOUT US

SOCIAL MEDIA

QUICK LINKS

CONTACT US